419 related articles for article (PubMed ID: 35101883)
1. Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study.
Jung HA; Park S; Choi YL; Lee SH; Ahn JS; Ahn MJ; Sun JM
Clin Cancer Res; 2022 Jun; 28(11):2321-2328. PubMed ID: 35101883
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
5. Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS ≥ 50%) NSCLC.
Takeyasu Y; Yoshida T; Shibaki R; Matsumoto Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Motoi N; Ohe Y
Clin Lung Cancer; 2021 Mar; 22(2):127-133.e3. PubMed ID: 33183972
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
[TBL] [Abstract][Full Text] [Related]
7. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
8. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression.
Aguilar EJ; Ricciuti B; Gainor JF; Kehl KL; Kravets S; Dahlberg S; Nishino M; Sholl LM; Adeni A; Subegdjo S; Khosrowjerdi S; Peterson RM; Digumarthy S; Liu C; Sauter J; Rizvi H; Arbour KC; Carter BW; Heymach JV; Altan M; Hellmann MD; Awad MM
Ann Oncol; 2019 Oct; 30(10):1653-1659. PubMed ID: 31435660
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.
Maggie Liu SY; Huang J; Deng JY; Xu CR; Yan HH; Yang MY; Li YS; Ke EE; Zheng MY; Wang Z; Lin JX; Gan B; Zhang XC; Chen HJ; Wang BC; Tu HY; Yang JJ; Zhong WZ; Li Y; Zhou Q; Wu YL
Sci Bull (Beijing); 2024 Feb; 69(4):535-543. PubMed ID: 38185589
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
16. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
17. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
Ellis PM; Vella ET; Ung YC
Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
[TBL] [Abstract][Full Text] [Related]
20. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
Zhang Y; Zhou H; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
